Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific Therapy
NCT ID: NCT06587074
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
150 participants
OBSERVATIONAL
2023-05-30
2025-07-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The demographic, clinical, functional, hemodynamic characteristics of patients, comorbidity, blood biomarker levels, received PAH-specific and symptomatic therapy will be assessed in order to determine the clinical characteristics of patients with IPAH.
The prospective part of study will include 50 patients with IPAH.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics
NCT01185730
The Exercise Capacity and Quality of Life in the Patients With IPAH and Secondary PH
NCT02647060
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
NCT05372263
Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension
NCT02647034
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
No interventions assigned to this group
Group 2
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* verified diagnosis of IPAH
Exclusion Criteria
* Other etiology op PAH,
* ischemic heart disease confirmed by MSCT of the coronary arteries or coronary angiography;
* diseases of the musculoskeletal system that prevent 6MWT
* severe liver dysfunction (more than 9 points on the Child-Pugh scale, class C)
* severe renal dysfunction (CC less than 15 ml/min), need for hemodialysis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Russian Cardiology Research and Production Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tamila V. Martynyuk, MD, PhD
Professor, Head of pulmonary hypertension department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tamila V Martyunuk, Yes
Role: PRINCIPAL_INVESTIGATOR
Russian National Cardiology Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Russian National Cardilogy Reasearch Center
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHAM-3232
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.